Category

Androgen Receptor Antagonist

Generic Name

Enzalutamide

Formulation

Each softgel capsule contains 40mg enzalutamide

Indication

  • For the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

  • For the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

Dosage

The recommended dose is 160 mg Enzalutamide (Xtandi®) (four 40 mg capsules) as a single oral daily dose.

Contraindication

Hypersensitivity to enzalutamide or to any of its excipients.
Women who are or may become pregnant.

Packaging

Box of 112’s softgel capsules (4 capsule per pouch)